GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year
BioSpace
Nuvalent Bio is GSK's third big-ticket purchase this year, after the pharma dropped $2.2 billion in January for RAPT Therapeutics and $950 million in February for 35Pharma.
pharminent
June 9, 2026 (Last updated: June 9, 2026)
BioSpace
Nuvalent Bio is GSK’s third big-ticket purchase this year, after the pharma dropped $2.2 billion in January for RAPT Therapeutics and $950 million in February for 35Pharma.
